Clinical Research Directory
Browse clinical research sites, groups, and studies.
Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDS
Sponsor: Washington University School of Medicine
Summary
This is a single institution, prospective study of the whole genome sequencing assay, ChromoSeq. Using prospectively collected patient data, coupled with physician surveys, the investigators seek to determine the feasibility of implementing ChromoSeq in addition to standard genomic testing, for patients with the diagnoses of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Official title: A Prospective Study of Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDS
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
325
Start Date
2021-09-17
Completion Date
2027-12-31
Last Updated
2025-10-16
Healthy Volunteers
Yes
Interventions
ChromoSeq
Novel, streamlined whole genome sequencing approach
Locations (1)
Washington University School of Medicine
St Louis, Missouri, United States